Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Alphamab Co Ltd (9966 HK)
Watchlist
144
Analysis
Health Care
•
China
Alphamab Oncology produces and sells drugs. The Company manufactures and sells tumor immunobiology macromolecular targeted drug and other products. Alphamab Oncology provides services worldwide.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Alibaba
•
16 Jan 2020 14:57
2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
Ke Yan, CFA, FRM
Follow
723 Views
Share
bullish
•
Alibaba
•
08 Jan 2020 17:38
2019 Hong Kong IPO Analytics: Highlight of Brokers’ and Sectors’ Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
Ke Yan, CFA, FRM
Follow
854 Views
Share
bullish
•
Alphamab Co Ltd
•
11 Dec 2019 18:18
Alphamab Oncology: Trading Debut, Valuation Scenario Analysis
Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
Arun George
Follow
646 Views
Share
bullish
•
Alphamab Co Ltd
•
11 Dec 2019 17:20
Alphamab (康宁杰瑞) IPO: Allocation and Buy-Level for the Hot Deal
Alphamab, the leading bispecific antibodies player in China, raised USD 220 million at HKD 10.2 per share. In this insight, we will cover the...
Ke Yan, CFA, FRM
Follow
660 Views
Share
bullish
•
Alphamab Co Ltd
•
08 Dec 2019 13:19
ECM Weekly (8 Dec 2019) - OneConnect, JS Global, Renrui, Poly Property, Freee, Burger King India
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This...
Zhen Zhou, Toh
682 Views
Share
First
Previous
24
25
26
27
28
29
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x